XBiotech Inc. (NASDAQ:XBIT - Get Free Report)'s share price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $3.37 and traded as high as $3.46. XBiotech shares last traded at $3.30, with a volume of 21,241 shares.
XBiotech Stock Performance
The stock's fifty day simple moving average is $3.33 and its 200-day simple moving average is $5.35. The stock has a market cap of $94.51 million, a P/E ratio of -2.87 and a beta of 1.25.
XBiotech (NASDAQ:XBIT - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its stake in XBiotech by 68.2% during the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock worth $58,000 after buying an additional 5,930 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of XBiotech during the 4th quarter valued at approximately $58,000. Bank of America Corp DE increased its position in XBiotech by 42.0% during the 4th quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock worth $79,000 after purchasing an additional 5,887 shares in the last quarter. Jane Street Group LLC bought a new position in XBiotech in the 3rd quarter valued at approximately $86,000. Finally, MetLife Investment Management LLC acquired a new stake in XBiotech in the third quarter valued at approximately $94,000. Institutional investors own 55.70% of the company's stock.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Recommended Stories
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
